Table 1.
Demographic and clinical characteristics of the study population
| 1° vaccine | ChAdOx | ChAdOx | ChAdOx | BNT | mRNA-1273 | |
|---|---|---|---|---|---|---|
| 2° vaccine | ChAdOx1 | BNT2 | mRNA-12733 | BNT | mRNA-1273 | |
| n = 62 | n = 66 | n = 101 | n = 43 | n = 58 | p value | |
| Years of age (mean ± SD) | 52.5 ± 10.9 | 45.0 ± 10.9 | 38.2 ± 13.7 | 52.9 ± 18.7 | 41.9 ± 15.2 | <0.0001§ |
| Female gender, n (%) | 41 (66.1) | 53 (80.3) | 82 (81.2) | 26 (60.5) | 38 (65.5) | 0.020† |
| Weeks between 1° and 2° vaccination, (mean ± SD) | 11.9 ± 1.1 | 11.7 ± 1.0 | 12.0 ± 0.7 | 5.4 ± 1.0 | 5.9 ± 0.2 | |
| Analysis time [days after 2° vaccination], median (IQR) | 14 (2.25) | 14 (1) | 14 (1) | 14 (2) | 15 (2) | |
|
Differential blood cell counts |
n = 62 | n = 65 | n = 101 | n = 41 | n = 57 | |
|
Leukocytes (cells/µl), median (IQR) |
7000 (2400) |
6400 (2000) |
6800 (1850) |
6100 (2300) |
7700 (2550) |
0.018‡ |
| Granulocytes (cells/µl), median (IQR) |
4014 (1715) |
3856 (1391) |
4100 (1363) |
3611 (2176) |
4617 (1981) |
0.006‡ |
|
Monocytes (cells/µl), median (IQR) |
561 (267) |
546 (233) |
531 (173) |
520 (217) |
568 (176) |
0.211‡ |
| Lymphocytes (cells/µl), median (IQR) |
2174 (1045) |
2103 (899) |
2170 (828) |
2189 (786) |
2241 (1127) |
0.720‡ |
|
CD3 T cells (cells/µl), median (IQR)# |
1527 (817) |
1524 (735) |
1498 (696) |
1567 (663) |
1636 (890) |
0.840‡ |
|
CD4 T cells (cells/µl), median (IQR) # |
919 (645) |
962 (413) |
937 (448) |
1031 (526) |
1066 (627) |
0.863‡ |
|
CD8 T cells (cells/µl), median (IQR) # |
383 (236) |
385 (271) |
396 (241) |
340 (259) |
388 (266) |
0.448‡ |
|
CD19 B cells (cells/µl), median (IQR)# |
204 (145) |
205 (135) |
202 (126) |
189 (168) |
244 (148) |
0.529‡ |
|
Plasmablasts (cells/µl), median (IQR)# |
0.478 (0.696) |
0.483 (0.722) |
0.528 (0.473) |
0.471 (0.476) |
0.868 (0.785) |
0.001‡ |
1Refers to ChAdOx1-nCoV-19 by AstraZeneca; 2Refers to BNT162b2 by BioNTech/Pfizer, ³Refers to mRNA-1273 by Moderna; #B and T-cell counts were calculated on 61 ChAdOx-ChAdOx, 64 ChAdOx-BNT, 101 ChAdOx-mRNA-1273, 39 BNT-BNT, and 57 mRNA-1273-mRNA-1273 vaccinated individuals, respectively. §Ordinary one-way ANOVA with Tukey´s multiple comparisons test. †X2 test; ‡two-sided Kruskal–Wallis test; source data are provided as a Source Data file.